Primary CNS posttransplant lymphoproliferative disease (PTLD): An international report of 84 cases in the modern era

A. M. Evens*, S. Choquet, A. R. Kroll-Desrosiers, D. Jagadeesh, S. M. Smith, F. Morschhauser, V. Leblond, R. Roy, B. Barton, L. I. Gordon, M. K. Gandhi, D. Dierickx, D. Schiff, T. M. Habermann, R. Trappe

*Corresponding author for this work

Research output: Contribution to journalArticle

77 Scopus citations

Abstract

We performed a multicenter, International analysis of solid organ transplant (SOT)-related primary central nervous system (PCNS) posttransplant lymphoproliferative disease (PTLD). Among 84 PCNS PTLD patients, median time of SOT-to-PTLD was 54 months, 79% had kidney SOT, histology was monomorphic in 83% and tumor was EBV+ in 94%. Further, 33% had deep brain involvement, 10% had CSF involvement, while none had ocular disease. Immunosuppression was reduced in 93%; additional first-line therapy included high-dose methotrexate (48%), high-dose cytarabine (33%), brain radiation (24%) and/or rituximab (44%). The overall response rate was 60%, while treatment-related mortality was 13%. With 42-month median follow-up, three-year progression-free survival (PFS) and overall survival (OS) were 32% and 43%, respectively. There was a trend on univariable analysis for improved PFS for patients who received rituximab and/or high-dose cytarabine. On multivariable Cox regression, poor performance status predicted inferior PFS (HR 2.61, 95% CI 1.32-5.17, p = 0.006), while increased LDH portended inferior OS (HR 4.16, 95% CI 1.29-13.46, p = 0.02). Moreover, lack of response to first-line therapy was the most dominant prognostic factor on multivariable analysis (HR 8.70, 95% CI 2.56-29.57, p = 0.0005). Altogether, PCNS PTLD appears to represent a distinct clinicopathologic entity within the PTLD spectrum that is associated with renal SOT, occurs late, is monomorphic and retains EBV positivity. In an international analysis of solid organ transplant recipients with primary central nervous system posttransplant lymphoproliferative disease, the authors find that the disease is associated with renal transplantation, typically occurs late and retains EBV positivity, and the dominant prognostic factor for survival is response to first-line therapy.

Original languageEnglish (US)
Pages (from-to)1512-1522
Number of pages11
JournalAmerican Journal of Transplantation
Volume13
Issue number6
DOIs
StatePublished - Jun 1 2013

Keywords

  • CNS
  • PTLD
  • lymphoma
  • prognosis
  • rituximab

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Primary CNS posttransplant lymphoproliferative disease (PTLD): An international report of 84 cases in the modern era'. Together they form a unique fingerprint.

  • Cite this

    Evens, A. M., Choquet, S., Kroll-Desrosiers, A. R., Jagadeesh, D., Smith, S. M., Morschhauser, F., Leblond, V., Roy, R., Barton, B., Gordon, L. I., Gandhi, M. K., Dierickx, D., Schiff, D., Habermann, T. M., & Trappe, R. (2013). Primary CNS posttransplant lymphoproliferative disease (PTLD): An international report of 84 cases in the modern era. American Journal of Transplantation, 13(6), 1512-1522. https://doi.org/10.1111/ajt.12211